(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 April 2013 (04.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/049234 A3

(51) **International Patent Classification**:
C07K 14/50 (2006.01) *C07K 14/605* (2006.01)

(21) **International Application Number**:
PCT/US2012/057371

(22) **International Filing Date**:
26 September 2012 (26.09.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/539,290 26 September 2011 (26.09.2011) US

(71) **Applicants** *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **IRM LLC** [—/US]; a Delaware Limited, Liability Company, 131 Front Street, PO Box HM 2899, Bermuda, HM LX (BM).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **BOETTCHER, Brian R.** [US/US]; Novartis Institutes for BioMedical, Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **CAPLAN, Shari L.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **CELLITTI, Susan E.** [US/US]; Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **DANIELS, Douglas S.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **HAMAMATSU, Norio** [JP/US]; Novartis Institutes for BioMedical Research, Inc, 100 Technology Square, Cambridge, Massachusetts 02139 (US). **GEIER-STANGER, Bernhard Hubert** [DE/US]; Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LICHT, Stuart** [US/US]; 100 Memorial Drive, Cambridge, Massachusetts 02142 (US). **LOEW, Andreas** [DE/US]; Novartis Institutes for BioMedical, Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **WELDON, Stephen Craig** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US).

(74) **Agent**: **PAGLIERANI, Paul J.**; Novartis Institutes for BioMedical, Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
3 January 2014

WO 2013/049234 A3

(54) **Title**: DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS

(57) **Abstract**: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.